¿¬°£Á¤º¸ ¼­ºñ½º
»óǰÄÚµå
960919

¹Ì±¹ÀÇ ¸Á¸· ½ÃÀå : ºÐ±âº° ¾÷µ¥ÀÌÆ®

US Retina Quarterly Update, Q2 - 2023: Analysis of Historical Trends and Latest Developments

¹ßÇàÁ¤º¸: | ¸®¼­Ä¡»ç: Market Scope, LLC | ÆäÀÌÁö Á¤º¸: ¿µ¹®

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸Á¸·(Retina) ½ÃÀå¿¡ ´ëÇØ ºÐ±âº°·Î ¹Ì±¹ÀÇ ¸Á¸· Àü¹®°¡¸¦ ´ë»óÀ¸·Î Á¶»ç¸¦ ½Ç½ÃÇÏ°í µ¥ÀÌÅ͸¦ ¼öÁýÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú¸¦ ºÐ¼®ÇßÀ¸¸ç, ºÐ±âº°·Î ¹Ý¿µµÇ´Â º¸°í¼­´Â ÇöÀç ½ÃÀå »óȲÀ» Á¤È®ÇÏ°Ô Æò°¡¡¤ÆÄ¾ÇÇÒ ¼ö ÀÖ¾î ÀÇ»ç°áÁ¤ ÇÁ·Î¼¼½º °³¼±À» ¸ñÀûÀ¸·Î Çϰí, ¸Á¸· Ä¡·á, Á¦Ç° »ç¿ë°ú ½ÃÀå Á¡À¯À², Á¦Ç° ä¿ë °èȹ, Àǻ翡 ÀÇÇÑ ÀǾàǰ¡¤¼ö¼ú ±â±¸ Æò°¡ µîÀ» Æ÷ÇÔÇÕ´Ï´Ù.

°¢ °»½Å¿¡´Â ¿¬Áß ¿¹Ãø, Àü³âµµ¿ÍÀÇ ºñ±³, µ¿Ç⠺м®ÀÌ Æ÷ÇԵ˴ϴÙ.

¿¬ 4ȸ, ¹Ì±¹ ¸Á¸· ½ÃÀåÀÇ ÁÖ¿ä ÁöÇ¥¸¦ ÃøÁ¤¡¤ºÐ¼®Çϰí ÀÖ½À´Ï´Ù.

  • Áúȯº° ¹× Á¦Ç°º° À¯¸®Ã¼³»(IVT) ÁÖ»ç
  • Eylea, Lucentis, Avastin, Macugen, Visudyne PDTÀÇ »ç¿ë
  • ´ç´¢º´¼º Ȳ¹ÝºÎÁ¾(DME) Ä¡·á
  • ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå »ç¿ë
  • ±¤ÀÀ°í·®°ú ±¤ÀÀ°íÁ¦ »ç¿ë
  • À¯¸®Ã¼ÀýÁ¦·®°ú À§Ä¡
  • À¯¸®Ã¼ÀýÁ¦±âÀÇ »ç¿ë°ú ½ÃÀå Á¡À¯À²
  • ÀçÀÌ¿ë °¡´É¡¤ÀÏȸ¿ë ±â±¸
  • °¡½ÃÈ­Á¦

°»½Å Á¤º¸¿¡´Â Áö³­ ¸î ³â°£ ¼öÁýµÈ Á¤º¸¿ÍÀÇ ºñ±³¿¡ ±â¹ÝÇÑ µ¿Ç⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¹Ì±¹ÀÇ ¸Á¸· ¼ö¼ú(IVT ÁÖ»ç Æ÷ÇÔ) ¿¬Áß ¿¹Ãø°ú Àü³â°úÀÇ ºñ±³µµ ½Ç½ÃÇß½À´Ï´Ù.

KSM 20.10.21

Our coverage of the US retina market includes a quarterly surveying process that targets and collects data from retina specialists. The resulting data are analyzed and presented in our US Retina Surgery Quarterly Updates. These updates are designed to improve your decision-making process with an assessment of current market conditions and the identification of significant market trends -- including retinal patient care, product use and market share, product adoption plans, and doctors' evaluations of pharmaceuticals and surgical equipment.

Each update includes full-year forecasts, comparisons with prior years, and trend analysis.

We measure and analyze key metrics of the US retinal market four times per year, including:

  • IVT injections by disease and product;
  • Use of Eylea, Lucentis, Avastin, Macugen, and Visudyne PDT;
  • DME treatments;
  • Corticosteroid use;
  • Photocoagulation volume and photocoagulators used;
  • Vitrectomy volume and location;
  • Vitrectomy machine use and market share;
  • Reusable and disposable instruments.
  • Visualization agents

Our updates include trend analysis based on comparisons with information gathered in previous years. We also provide a full-year forecast for US retinal procedures (including IVT injections) and a comparison with volumes during the prior year.

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦